Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:08189'
s FCF Margin % Range Over the Past 10 Years
Min: -12.02 Med: -6.42 Max: 5.95
Current: -11.87
During the past 13 years, the highest FCF Margin % of Tianjin TEDA Biomedical Engineering Co was 5.95%. The lowest was -12.02%. And the median was -6.42%.
HKSE:08189's FCF Margin % is ranked worse than 79.44% of 248
companies
in the Agriculture industry
Industry Median: 0.265
vs HKSE:08189: -11.87
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co FCF Margin % Chart
Tianjin TEDA Biomedical Engineering Co Annual Data
HKSE:08189 vs CTVA, CF, MOS: FCF Margin % Comparison
For the Agricultural Inputs subindustry, Tianjin TEDA Biomedical Engineering Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianjin TEDA Biomedical Engineering Co FCF Margin % vs Agriculture Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianjin TEDA Biomedical Engineering Co (HKSE:08189) has a FCF Margin % of 12.27% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. According to the industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #197 out of 248 companies in the Agriculture industry, placing it in the top 79.4%.
Is Tianjin TEDA Biomedical Engineering Co's FCF Margin % too high?
Tianjin TEDA Biomedical Engineering Co's current FCF Margin % is 12.27%. The Agriculture industry median FCF Margin % is 0.27. Tianjin TEDA Biomedical Engineering Co's value of 12.27% is 4530.2% above this industry median. Based on the distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #197 out of 248 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Tianjin TEDA Biomedical Engineering Co has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tianjin TEDA Biomedical Engineering Co's FCF Margin % compare to CTVA and CF?
According to the Agriculture industry distribution chart, Tianjin TEDA Biomedical Engineering Co ranks #197 out of 248 companies for FCF Margin %. This places Tianjin TEDA Biomedical Engineering Co in the lower half of its industry. The industry median FCF Margin % is 0.27. Tianjin TEDA Biomedical Engineering Co's value of 12.27% is 4530.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for an Agriculture company?
The median FCF Margin % among Agriculture companies is 0.27, based on 248 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tianjin TEDA Biomedical Engineering Co's current FCF Margin % of 12.27% is 4530.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Tianjin TEDA Biomedical Engineering Co and its competitors. For the Agriculture industry, the median FCF Margin % is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianjin TEDA Biomedical Engineering Co's current FCF Margin % is 12.27%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianjin TEDA Biomedical Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co (HKSE:08189) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.19, compared to a current price of HK$0.26 — trading 34.2% above its estimated fair value. The current FCF Margin % is 12.27% and 4530.2% above the Agriculture industry median of 0.27. Tianjin TEDA Biomedical Engineering Co's overall GF Score™ is 28/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Tianjin TEDA Biomedical Engineering Co (HKSE:08189), the current FCF Margin % is 12.27% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianjin TEDA Biomedical Engineering Co (HKSE:08189) Overvalued in 2026?
Based on GuruFocus' analysis, Tianjin TEDA Biomedical Engineering Co stock appears to be overvalued.
The current stock price of HK$0.26 is trading 34.2% above its estimated GF Value™ of HK$0.19.
GuruFocus considers Tianjin TEDA Biomedical Engineering Co to be Significantly Overvalued.
Key valuation signals for HKSE:08189:
FCF Margin %: 12.27%
GF Value™: HK$0.19 vs. price of HK$0.26 (34.2% above fair value)
Industry Position: 4530.2% above the Agriculture median (#197 of 248)
No single metric tells the full story. See the HKSE:08189 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianjin TEDA Biomedical Engineering Co Ltd principally engages in manufacture and sale of biological compound fertiliser products and elderly care and health care services and related products. The group is principally engaged in manufacturing and selling biological compound fertilisers, AI health & elderly care products and services. It operates in two segments namely; fertilisers products; and AI health & elderly care products and services. The company generates a majority of its revenue from the Fertilisers products segment. The People's Republic of China is the primary geographical market for the company.
28GF Score
Get the complete analysis for HKSE:08189
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08189 has been successfully added to your 
